Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Vistagen Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 48 | 51 | +3 |
| Shares | 15.9M | 15.5M | −449.8K (−2.8%) |
| Value | $39.0M | $30.3M | −$8.75M (−22.4%) |
New holders (6)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 95,051 | $190.1K | 0.00% |
| Marshall Wace, LLP | 34,638 | $69.3K | 0.00% |
| Virtu Financial LLC | 22,946 | $46.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 7,721 | $15.4K | 0.00% |
| Truvestments Capital LLC | 7,155 | $14.3K | 0.00% |
| Raymond James Financial Inc | 6,410 | $12.8K | 0.00% |
Sold out (3)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Prosperity Wealth Management, Inc. | 27,600 | $69.0K |
| Cubist Systematic Strategies, LLC | 10,088 | $25.2K |
| SJS Investment Consulting Inc. | 100 | $250 |